Orexin neurons within the lateral hypothalamus play a crucial role in the promotion and maintenance of arousal. Studies have strongly suggested that orexin neurons are an important target in endogenous adenosine-regulated sleep homeostasis. Orexin A induces a robust increase in the firing activity of orexin neurons, while adenosine has an inhibitory effect. Whether the excitatory action of orexins in the lateral hypothalamus actually promotes wakefulness and reverses the sleep-producing effect of adenosine in vivo is less clear. In this study, electroencephalographic and electromyographic recordings were used to investigate the effects of orexin A and adenosine on sleep and wakefulness in rats. We found that microinjection of orexin A into the lateral hypothalamus increased wakefulness with a concomitant reduction of sleep during the first 3 h of post-injection recording, and this was completely blocked by a selective antagonist for orexin receptor 1, SB 334867. The enhancement of wakefulness also occurred after application of the excitatory neurotransmitter glutamate in the fi rst 3 h post-injection. However, in the presence of the NMDA receptor antagonist APV, orexin A did not induce any change of sleep and wakefulness in the first 3 h. Further, exogenous application of adenosine into the lateral hypothalamus induced a marked increase of sleep in the fi rst 3-h post-injection. No signifi cant change in sleep and wakefulness was detected after adenosine application followed by orexin A administration into the same brain area. These findings suggest that the sleep-promoting action of adenosine can be reversed by orexin A applied to the lateral hypothalamus, perhaps by exciting glutamatergic input to orexin neurons via the action of orexin receptor 1.
INTRODUCTION
The neuropeptides orexin A and orexin B, produced by hypothalamic neurons, play a crucial role in the promotion and maintenance of wakefulness [1] [2] [3] [4] . This arousalpromoting effect of orexins may be realized by excitatory actions on multiple subcortical arousal systems and the cerebral cortex [5] [6] [7] [8] . Two G protein-coupled receptors (orexin receptor 1 and 2) are involved in maintaining a long, consolidated awake period [5, 9, 10] . Loss of orexin neurons impairs wakefulness [11] , whereas their stimulation facilitates wakefulness [3] . Thus, modulation of orexin neurons is critical in the regulation of sleep and wakefulness [12] [13] [14] .
In vitro electrophysiological studies have demonstrated that orexin A directly excites local glutamatergic neurons in the lateral hypothalamus, inducing a substantial depolarization and a robust increase in the fi ring of orexin neurons [15, 16] . Whether the excitatory actions of orexins on orexin neurons in the hypothalamus actually promote and maintain wakefulness in vivo is still unknown.
In addition, abundant evidence has suggested that orexin neurons are a potential target in the regulation of sleep homeostasis by endogenous adenosine. In vivo, local perfusion of an adenosine receptor agonist into the stainless-steel electrodes for EEG recording were screwed through the skull onto the dura over the frontal cortex (anterior: −3 mm; lateral: 3.5 mm) and the parietal cortex (anterior: −4 mm; lateral: −3 mm) [22] . Two insulated stainless-steel, Teflon-coated wires for monitoring EMG signals were placed bilaterally into the trapezius muscles.
In addition, at the stereotaxic coordinates anterior, −3. The tip of this guide cannula was 2 mm above the lateral hypothalamus. Each rat was allowed at least 7 days for recovery from surgery, and was habituated individually to the experimental conditions for 3-4 days, where it was connected to the EEG/EMG recording system by a fl exible cable.
Microinjection Procedure
All microinjections were unilateral and performed between 09:30 and 10:00 as described previously [19] . Then the rats were reconnected and recorded from 10:00. Behavioral states were recorded continuously for 4 days, except during microinjections. At the time of infusion, the rats were gently restrained in a towel and an injection cannula was inserted into the guide cannula for microinjection of a volume of 0.2 μL, at a rate of 0.1 μL/min. A constant injection rate was maintained using a syringe pump (CMA 402, CMA/ Microdialysis, Solna, Sweden). The injection cannula was kept in place for 1-2 min to allow diffusion from the cannula tip.
Procedure 1: Effect of orexin A administration on spontaneous sleep and wakefulness Seven rats were used in this experiment. The experimental protocol is outlined in Table 1 . On day 1, EEG and EMG signals without any injection were recorded as baseline. On the second day, either ACSF or orexin A (40 pmol) was microinjected into the lateral hypothalamus [19] . After recovery on day 3, these animals were given either ACSF or 40 pmol orexin A (whichever had not been injected on the second day) injected into the lateral hypothalamus on day 4. One week after completion of this session, another session using 10 pmol orexin A was initiated. Rats were randomly assigned to receive ACSF or orexin A.
Procedure 2: Effect of orexin receptor 1 antagonist application on spontaneous sleep and wakefulness
A total of twelve rats were used. On day 2, the rats (n = 6) randomly received unilateral microinjection of ACSF containing 10% dimethylsulfoxide (DMSO) or SB 334867 (0.5 μg) followed by ACSF application at the same site 5-10 min later (Table 1) . After one-day recovery, the animals were microinjected with ACSF following DMSO or SB 334857 (0.5 μg) (whichever was not applied on the second day) on day 4. Another group of animals (n = 6) received DMSO or SB 334867 (0.5 μg) (whichever was not applied on the second day) followed by orexin A (10 pmol) application on day 2 or 4 randomly. by SLEEPSIGN software, according to the methods described previously [23] [24] [25] .
Histological Localization of Microinjection Site
After completion of the experiments, all rats were killed under deep pentobarbital anesthesia and perfused with cold heparinized 0.9% saline followed by perfusion of 4% paraformaldehyde. The brain was isolated, blocked, and processed for orexin A immunohistochemistry [20] , to illustrate the locations of orexin neurons relative to the track of the drug injector cannula.
Statistical Analysis
All data are presented as mean ± SEM. Data analyses were 
RESULTS

Identifi cation of the Site of Drug Delivery
Three continuous coronal schematics of rat brain through lateral hypothalamus including orexin neurons demonstrated that all microinjection sites were localized in the perifornical lateral hypothalamus and adjoining areas between AP −3.1 and −3.6 mm (Fig. 1A ) [22] , consistent with previous reports [17] . Based on the location of microinjection sites, the areas of perfused drugs were confirmed to include the orexin neurons in the lateral hypothalamus. 
Arousal-promoting Effect of Orexin
Orexin A Promotes Arousal through Activation of Orexin Receptor 1
A preliminary study has demonstrated that a selective antagonist for orexin receptor 1, SB 334867, reverses the arousal-promoting action of orexin A in anesthetized animals [26] . In this study, we further tested the effect of SB 334867 on spontaneous sleep and wakefulness in conscious rats. Orexin A (10 pmol) increased the time spent in wakefulness and reduced REM and NREM sleep correspondingly (Newman-Keuls test, P <0.01), while pretreatment with SB 334867 (0.5 μg) blocked these effects (Newman-Keuls test, P >0.05). In addition, compared to vehicle (DMSO) followed by ACSF injection, administration of SB 334867 (0.5 μg) with ACSF into the lateral hypothalamus had no effect on the three behavioral states during the first 3-h session (Newman-Keuls test, P >0.05) (Fig. 2) .
Involvement of Glutamatergic Synaptic Transmission in Orexin A-induced Promotion of Wakefulness
In vitro electrophysiological experiments have demonstrated that the excitatory action of orexin A on orexin neurons in the lateral hypothalamus is achieved by increasing the excitatory glutamatergic synaptic input to these neurons [15, 16] .
Thus, we further explored the role of the glutamatergic And signifi cant differences in the time in wakefulness, REM and NREM sleep during the first 3 h-session were found between ACSF and APV followed by orexin A (NewmanKeuls test, P <0.01).
Effect of Orexin A on Adenosine-induced Changes of
Sleep and Wakefulness
Recent behavioral experiments with adenosine antagonists in vivo have suggested that orexin neurons are another important target involved in the hypnotic action of adenosine [16, 17, 19, 27] . In this study, we further explored the role of exogenous adenosine in the regulation of sleep and wakefulness in the lateral hypothalamus. Analysis of the (Newman-Keuls test, P >0.05) (Fig. 4A) .
Whether the excitatory effect of orexin A on these orexin neurons could reverse the sleep propensity induced by adenosine was little known. During the first 3 h postinjection, compared to ACSF microinjection, adenosine (10 nmol) administration induced an increase in REM and NREM sleep with a concomitant reduction of wakefulness (Newman-Keuls test, P <0.01). However, no significant changes in behavioral state were found after application of 10 nmol adenosine followed by 10 pmol orexin A during the fi rst 3 h post-injection (Newman-Keuls test, P >0.05) (Fig.   4B ).
DISCUSSION
The main finding of this study was that exogenous The arousal-promoting action of the orexin system in the central nervous system (CNS) by activation of multiple subcortical arousal systems including the basal forebrain [28] , tuberomammillary nucleus [23, 29] and locus coeruleus [30] has been well documented. In this study, we found that enhancement of wakefulness in rats was induced by microinjection of orexin A into the lateral hypothalamus where these orexin neurons are located. This suggests that orexins exert a strong excitatory effect in the lateral hypothalamus, and this is mediated by orexin receptor 1, in that pretreatment with a selective orexin receptor 1 antagonist completely blocked the arousal-promoting action of orexin A. In vitro electrophysiological studies have demonstrated that the exogenous application of orexin increases the firing rates of orexin neurons through the activation of glutamatergic input to these neurons [15, 16] .
Consistently in this study, the arousal-promoting effect was not detected after blockade of glutamatergic transmission to these neurons using an NMDA receptor antagonist, strongly suggesting that the arousal-promoting action of orexin A is realized by directly exciting glutamatergic input to orexin neurons through the activation of orexin receptor 1.
Thus, these fi ndings demonstrate that the positive feedback from excitatory glutamatergic input to orexin neurons may function in keeping orexin neurons firing continuously in wakefulness, which is essential for orexins to excite subcortical systems to promote and maintain wakefulness.
Consistent with the previous reports [31, 32] , we also found that administration of glutamate into the lateral hypothalamus increased wakefulness in a dose-dependent showed that microinjection of AMPA into the perifornical lateral hypothalamus of rats increases the number of orexin neurons immunoreactive for c-Fos [32] .
In addition to the key role in promoting wakefulness, abundant evidence has demonstrated that orexin neurons are a potential target in the sleep-producing effect of endogenous adenosine, in which blockade of adenosine A1 receptors in the lateral hypothalamus induces a signifi cant increase in wakefulness with a concomitant reduction in sleep [17, 19] . Consistently, we found that the exogenous application of adenosine into the lateral hypothalamus enhanced sleep. These data confirmed the involvement of orexin neurons in the regulation of sleep homeostasis by endogenous adenosine. Moreover, a study by Liu et al.
revealed that the mechanism underlying this adenosineinduced suppression may be through inhibition of excitatory glutamatergic synaptic input to orexin neurons via adenosine A1 receptors [27] .
Furthermore, we found no significant difference in sleep and wakefulness between control and orexin A following adenosine injection, which suggests that this sleep-promoting effect of exogenous adenosine can be blocked by application of orexin A into the same area.
This suggests that the excitatory effect of orexin A on orexin neurons in the lateral hypothalamus reverses the sleep propensity induced by adenosine. Neuronal activity in wakefulness is associated with increased neuronal metabolism. As a product of cell metabolism and is ubiquity in the CNS, adenosine accumulates during wakefulness and progressively increases the propensity to sleep [33, 34] . Indeed, our previous studies have provided evidence that under sustained or stronger synaptic transmission in orexin neurons, endogenous adenosine is generated and inhibits the excitability of orexin neurons via inhibiting glutamatergic transmission in acute hypothalamic slices [16] . Moreover, the previous study in vitro showed that orexin excites the orexin neurons via local glutamatergic transmission [15] . Thus, the indirect excitatory effect of orexin might offset the inhibitory action of adenosine on orexin neurons and consequently reverse the sleeppromoting effect of adenosine. The modulation of orexin neurons plays an important role in regulating sleep and wakefulness, especially under prolonged wakefulness in which sleep pressure is enhanced rapidly due to the large release of endogenous adenosine [35] . Caffeine, a nonselective adenosine receptor antagonist, is a widely used stimulant that effectively reverses the depressant effects of increasing sleep propensity [36] , although the sideeffect of drug-dependence has restricted its therapeutic use as an arousal-promoting agent [37] . It is therefore necessary to find other available drugs or measures to abolish the increase of sleep propensity. Our fi ndings of the reversal of the sleep-promoting effect by orexin A provides a possibility that orexins may be a potential candidate to reduce the sleep propensity induced by adenosine, independent of the blockade of adenosine receptors.
In conclusion, we speculate that pharmacological manipulation of the orexin system including orexin neurons 
